David Hung, Nuvation Bio president and CEO (Nuvation Bio)
FDA places partial clinical hold on David Hung biotech after certain cancer patients experience eye inflammation
Two and a half years after setting out on another foray into oncology R&D, a biotech headed by David Hung — of Medivation fame — has run …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.